VJVirtual | BASECAMP-1: developing Tmod CAR T-cell therapy for solid tumors

Diane Simeone, MD, NYU Langone Health, New York, NY, discusses the observational BASECAMP-1 (NCT04981119) study investigating solid tumor analysis for HLA loss of heterozygosity (LOH) and apheresis for CAR T- cell manufacturing. Although CAR-T cell therapy has demonstrated clinical outcomes in hematological malignancies, translating engineered T-cell therapies to solid tumors has proven difficult due to a lack of tumor-specific targets. Tmod addresses these challenges via utilization of dual-signaling receptors to create a therapeutic safety window whilst enabling for the delivery of a heavy payload. In this study, patients will be initially screened to identify germline HLA-A*02 heterozygosity. If HLA-A*02 heterozygosity is confirmed, the tumor will be analyzed to determine whether HLA-A*02 loss of heterozygosity (LOH) is present. Those with confirmed HLA-A*02 LOH will be candidates for leukapheresis. Banked T cells will be available for the autologous Phase I/II EVEREST-1 (NCT05736731) Tmod CAR T-cell therapy interventional study. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.